

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

Atezolizumab	Not in data
Carboplatin with Gemcitabine	0
Carboplatin with Paclitaxel	0
Carboplatin single or in any other combination	0
Cisplatin with Gemcitabine	<5
Cisplatin single or in any other combination	0
Nivolumab	Not in data
MVAC with G-CSF	0
Pembrolizumab	<5
Any other regimen including Paclitaxel	0
Any other chemo regimen	0

Other active systemic anti-cancer therapy [please state] 0

Palliative care only - Data not held; therefore this request is refused under section 17 of FOISA

Q2. Could you please provide the total number of patients with any treatment in the last three months for:

Total non-small cell lung cancer (NSCLC) 28

BRAF+ non-small cell lung cancer (NSCLC) Data not held; therefore this request is refused under section 17 of FOISA

Q3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

Afatinib	0
Alectinib	<5
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	Not in data
Atezolizumab monotherapy	<5
Bevacizumab	Not in data
Brigatinib	0
Ceritinib	0
Crizotinib	0
Dacomitinib	0
Dabrafenib with Trametinib	Not in data
Docetaxel	0
Durvalumab	<5
Erlotinib	0
Gefitinib	0
Gemcitabine	(with carboplatin 6)
Nintedanib with Docetaxel	<5
Nivolumab	<5
Osimertinib	<5
Paclitaxel	(with carboplatin and radiotherapy <5)
Pembrolizumab chemo in combination	<5
Pembrolizumab monotherapy	<5
Pemetrexed with Carboplatin	<5
Pemetrexed with Cisplatin	0
Vinorelbine and cisplatin/carboplatin	<5